Bristol-Myers Squibb Earnings: Did Opdivo & Elqiuis Sales Could Positively Impact Margins?

The situation has turned favorable for the company with promising new drugs in the cardiovascular, oncology and infectious diseases segments. Investors are betting on the company's ability to substantially expand its market in the next year or two. We believe the upcoming Q2 2015 earnings results, which BMY plans to announce on July 23rd, will be largely seen from the perspective of the developments just mentioned. More specifically, the focus will be on the ramp up of sales of Eliquis and Opdiv...